Patent · US Active

PTEFb inhibiting macrocyclic compounds

US11254690B2 · kind B2 · utility

1Cited by

8References

22Claims

0Family size

Assignees

Bayer Pharma Aktiengesellschaft · DE
BAYER HEALTHCARE LLC · DE

Inventors

Ulrich Lücking · Berlin, DE
Daniel Hog · Düsseldorf, DE
Clara Christ · Leverkusen, DE
Ulrike Sack · Berlin, DE
Franziska SIEGEL · Cambridge, US
Philip Lienau · Berlin, DE
Nicolas Werbeck · Berlin, DE

Key dates

Filing date	Mar 22, 2018
Grant date	Feb 22, 2022
Priority date	—
Expiry date	Mar 22, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.